from the link,http://www.ncbi.nlm.nih.gov/pubmed/19364933"RESULTS: Overall, 5 of 15 patients (33%) experienced adverse effects of [daclizumab] therapy."Is NIH wasting taxpayer dollars on researching this drug?Why? USA is the assignee of the US Patent 7575742See uspto.gov for yourself.search by Daclizumab (aka Zenapax)http://en.wikipedia.org/wiki/DaclizumabDaclizumab has ONLY 1 FDA approved use per wiki & in kidney transplantation.Check www.clinicaltrials.govFind 26 of 90 funded in full or part by INDUSTRYFind 48 of 90 funded fully or in part by NIHFind 16 of 90 funded by OTHER (also taxpayers)Compare to natalizumab (aka TYSABRI) @ www.clinicaltrials.govFind 34 of 36 funded in full or part by INDUSTRYFind 2 of 36 funded by OTHERFind 0 of 36 studies funded by in full or part by NIHTysabri has 2 FDA approved applicationsTysabri also linked to STEM CELLS increase in patients.Daclizumab is NOT linked to STEM CELLS except for 1 Pakistani!!! PubMed abstract???
JUST THE FACT WE YOU / WE ARE DISCUSSING THIS is good. The more that NIH avoiding TY is discussed the more evidence that TY is the better product emerges.ELN coould easily be a take out target in 2010 in the $25.00 area.
Your play? Buy BIIB! Tys and Dacli are partly BIIB's.